SAPAT, 1992 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of aspirin versus placebo in patients with stable chronic angina pectoris

        Z

Lancet 1992;340:1421-5  



Studied treatment aspirin 75 mg daily
Control treatment placebo
Concomittant treatmentsotalol for control of symptoms



Patients patients with stable chronic angina pectoris
Group sizes1009 / 1026



Blindness double blind Inclusion period
Follow-up duration 50 months Centers
Lost to FU geographical localisation Sweden
Primary endpoint myocardial infarction and sudden death Design Parallel groups
ArretTrt1109 (10.8%)
ArretTrt0100 (9.75%)
HypotheseSuperiority



EndpointX1N1X0N0TE95% CI non vascular death 18 1009 11 1026 1,66[0,78; 3,54] major bleeds - 1009 - 1026 no data Non fatal MI 40 1009 61 1026 0,67[0,44; 1,00] Non fatal stroke 21 1009 27 1026 0,79[0,44; 1,41] vascular death 53 1009 71 1026 0,76[0,53; 1,10] vascular event 111 1009 159 1026 0,71[0,55; 0,92]0,22,01,0

Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5     [PMID: 1360557]   link to pdf   add to Mendeley  



Registering number (see trial on clinicaltrials.gov)
Code Name